When the upregulation of BCL-XL induced in CLL cells by autologous activated T cells was evaluated, we found that both SPHK inhibitors reduced it, suggesting that SPHK2 may participate in this process. This evidence concerns the gene SPHK2 and B-cell chronic lymphocytic leukemia.